IRIS
GRASSADONIA, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.240
EU - Europa 2.966
AS - Asia 1.650
SA - Sud America 212
OC - Oceania 21
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 8.113
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.219
SG - Singapore 732
IT - Italia 632
IE - Irlanda 540
CN - Cina 488
SE - Svezia 362
UA - Ucraina 338
FR - Francia 321
GB - Regno Unito 251
TR - Turchia 225
DE - Germania 209
BR - Brasile 197
IN - India 83
RU - Federazione Russa 76
FI - Finlandia 73
VN - Vietnam 41
BE - Belgio 34
HK - Hong Kong 32
CZ - Repubblica Ceca 29
PL - Polonia 26
AT - Austria 17
AU - Australia 17
NL - Olanda 16
CA - Canada 14
LT - Lituania 10
TW - Taiwan 8
BD - Bangladesh 7
IQ - Iraq 7
EG - Egitto 6
ES - Italia 6
JP - Giappone 6
RO - Romania 6
EU - Europa 5
MX - Messico 5
AR - Argentina 4
CH - Svizzera 4
IL - Israele 4
MA - Marocco 4
NZ - Nuova Zelanda 4
ZA - Sudafrica 4
BO - Bolivia 3
PT - Portogallo 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
DZ - Algeria 2
EC - Ecuador 2
EE - Estonia 2
GR - Grecia 2
KR - Corea 2
LU - Lussemburgo 2
MT - Malta 2
NP - Nepal 2
PK - Pakistan 2
PY - Paraguay 2
VE - Venezuela 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CO - Colombia 1
DK - Danimarca 1
ID - Indonesia 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
LV - Lettonia 1
OM - Oman 1
PE - Perù 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 8.113
Salva come PNG Salva come JPEG
Città #
Chandler 657
Dublin 528
Singapore 515
Jacksonville 436
Princeton 203
Southend 166
The Dalles 144
Izmir 132
Ashburn 131
Nanjing 128
Beijing 102
Santa Clara 99
Chieti 91
Pescara 89
Ann Arbor 84
Dearborn 84
Wilmington 84
Altamura 83
Boardman 66
Cambridge 62
Los Angeles 52
New York 44
Dong Ket 40
Munich 39
Nanchang 37
Brussels 32
Nuremberg 29
Hong Kong 28
Rome 28
Woodbridge 28
Washington 27
Brno 23
Hebei 22
Kunming 21
Shenyang 21
Tianjin 20
Norwalk 19
Jiaxing 18
Kraków 18
São Paulo 16
Milan 15
Falls Church 14
Changsha 13
Frankfurt am Main 13
Helsinki 13
Houston 12
Ancona 11
Grevenbroich 11
Amsterdam 10
Hangzhou 9
London 9
Melbourne 9
Vienna 9
Chicago 8
Guangzhou 8
Lappeenranta 8
Rio de Janeiro 8
Bristol 7
Changchun 7
Guarulhos 7
Seattle 7
Tappahannock 7
Augusta 6
Belo Horizonte 6
Cairo 6
Campinas 6
Corridonia 6
Hefei 6
Lanciano 6
Menlo Park 6
Oklahoma City 6
San Francisco 6
Taipei 6
Ascoli Piceno 5
Auburn Hills 5
Campina Grande 5
Edinburgh 5
Jinan 5
Lanzhou 5
Moscow 5
Romola 5
Brooklyn 4
Carini 4
Chennai 4
Dallas 4
Denver 4
Florence 4
Garden City 4
Istanbul 4
Loma Linda 4
L’Aquila 4
Montorio al Vomano 4
Mumbai 4
Napoli 4
Ottawa 4
Penne 4
Perth 4
Secaucus 4
Spoltore 4
Stockholm 4
Totale 4.843
Salva come PNG Salva come JPEG
Nome #
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 126
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 120
New Targets for Therapy in Pancreatic Cancer 117
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 115
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 111
The Role of the Environment and Type of Exercise on Acute Adrenal Modulation and Perceived Distress of Breast Cancer Survivors Practising Light-Intensity Physical Exercise 111
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 110
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 109
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 107
Occupational allergy: is there a role for nanoparticles? 106
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 106
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 105
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 105
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 105
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 104
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 103
The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function. 102
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 100
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 98
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 98
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 98
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 97
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 97
Exosomes as pleiotropic players in pancreatic cancer 97
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 96
Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells 96
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 95
Principali effetti collaterali delle terapie mediche 95
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 95
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 95
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 94
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 91
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 91
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 90
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 89
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 88
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 87
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 86
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 85
Tumor-derived microvesicles: The metastasomes. 85
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 84
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 84
Regolazione, funzione ed espressione genica dell’antigene tumore-associato 90K/AC-2 BP 83
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 81
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies 81
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 81
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 81
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 80
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 80
Circadian timing of chemotherapeutic agents:a phase II study of 5-fluoro-2-deoxyuridine in gastrointestinal cancer and renal cell carcinoma 79
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 78
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 77
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 77
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 76
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 76
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 76
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 75
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 75
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 75
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 75
Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? 74
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 73
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 72
Thyroglobulin autoregulation of thyroid-specific gene expression and follicular function 70
Possible role of thymidylate synthase level in hunan colorectal carcinoma: a new prognostic factor? 69
Drug repurposing, an attractive strategy in pancreatic cancer treatment: Preclinical and clinical updates 69
Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study 68
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 68
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 68
Prognostic value of a novel interferon-inducible 90K tumor antigen 67
Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid-specific gene expression. 67
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 67
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 67
Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study 66
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 66
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 66
Infusione cronomodulata di farmaci in oncologia 65
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 65
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 65
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 65
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 64
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 64
The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective 63
Effect of taxanes following anthracyclines on pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC) receiving primary systemic therapy (PST). 61
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 61
Current challenges in HER2-positive breast cancer 61
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 61
FPSE-HPLC-DAD metod for the quantification of anticancer drugs in human whole blood, plasma and urine 60
Thyroglobulin repression of thyroid transcription factor 1 (TTF-1) gene expression is mediated by decreased DNA binding of nuclear factor I proteins which control constitutive TTF-1 expression 59
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 54
Relationships between daily physical activity combinations and psychophysical health status of Italian breast cancer survivors 53
Prognostic value of gender and primary tumor location in metastatic colon cancer 52
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review 51
Eribulin in triple negative metastatic breast cancer: Critic interpretation of current evidence and projection for future scenarios 48
Pretreatment neutrophil-lymphocyte ratio (NLR) predicted overall survival (OS) for metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) patients who received monotherapy with immune checkpoint inhibitor as ipilimumab, nivolumab and pembrolizumab 48
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 47
Whole breast radiotherapy in cN0 early breast cancer patients with pathological sentinel lymph nodes (pN1mic, pN1a) without axillary dissection: preliminary results of the observational LISEN trial 46
Detection of Germline Mutations in a Cohort of 250 Relatives of Mutation Carriers in Multigene Panel: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 45
Effects of activity tracker-based counselling and live-web exercise on breast cancer survivors’ sleep and waking time during Italy’s COVID-19 lockdown 44
Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Functional Analyses 43
Totale 8.021
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 0 0 0 0 0 7
2020/2021605 97 8 99 9 36 114 18 19 41 61 40 63
2021/2022557 19 15 5 118 34 32 15 46 33 15 62 163
2022/20231.842 143 236 160 191 190 329 98 155 210 16 70 44
2023/20241.029 86 31 66 44 64 329 173 30 41 33 25 107
2024/20252.097 137 390 324 109 61 118 116 125 223 176 257 61
Totale 8.619